The Aeson® total artificial heart (A-TAH) has been developed as a total heart replacement for patients at risk of death from biventricular failure. We previously described endothelialization of the hybrid membrane inside A-TAH probably at the origin of acquired hemocompatibility. We aimed to quantify vasculogenic stem cells in peripheral blood of patients with long-term A-TAH implantation. Four male adult patients were included in this study. Peripheral blood mononuclear cells were collected before A-TAH implantation (T0) and after implantation at one month (T1), between two and five months (T2), and then between six and twelve months (T3). Supervised analysis of flow cytometry data confirmed the presence of the previously identified Lin-CD133+CD45- and Lin-CD34+ with different CD45 level intensities. Lin-CD133+CD45-, Lin-CD34+CD45- and Lin-CD34+CD45+ were not modulated after A-TAH implantation. However, we demonstrated a significant mobilization of Lin-CD34+CD45dim (p = 0.01) one month after A-TAH implantation regardless of the expression of CD133 or c-Kit. We then visualized data for the resulting clusters on a uniform manifold approximation and projection (UMAP) plot showing all single cells of the live Lin- and CD34+ events selected from down sampled files concatenated at T0 and T1. The three clusters upregulated at T1 are CD45dim clusters, confirming our results. In conclusion, using a flow cytometry approach, we demonstrated in A-TAH-transplanted patients a significant mobilization of Lin-CD34+CD45dim in peripheral blood one month after A-TAH implantation. Using a flow cytometry approach, we demonstrated in A-TAH transplanted patients a significant mobilization of Lin-CD34+CD45dim in peripheral blood one month after A-TAH implantation. This cell population could be at the origin of newly formed endothelial cells on top of hybrid membrane in Carmat bioprosthetic total artificial heart.

Cardiac Surgery Department and Biosurgical Research Lab AP HP Georges Pompidou European Hospital Université de Paris 75015 Paris France

Carmat SA Vélizy Villacoublay France

Department of Cardiovascular Surgery Institute for Clinical and Experimental Medicine Prague Czech Republic

Hematology and Biosurgical Research Lab AP HP Georges Pompidou European Hospital 75015 Paris France

Innovative Therapies in Haemostasis INSERM Université de Paris 75006 Paris France

Institut Curie Cytometry Platform 75006 Paris France

PARCC INSERM Université de Paris 75015 Paris France

Vascular Medicine Department and Georges Pompidou European Hospital AP HP 75015 Paris France

000      

00000naa a2200000 a 4500

001      

bmc22019627

003      

CZ-PrNML

005      

20220804135834.0

007      

ta

008      

220720s2021 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s12015-021-10270-3 $2 doi

035    __

$a (PubMed)34622384

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Guyonnet, Léa $u Institut Curie, Cytometry Platform, 75006, Paris, France

245    10

$a Elevated Circulating Stem Cells Level is Observed One Month After Implantation of Carmat Bioprosthetic Total Artificial Heart / $c L. Guyonnet, G. Detriché, N. Gendron, A. Philippe, C. Latremouille, L. Soret, A. Capel, C. Peronino, P. Jansen, P. Ivak, A. Carpentier, T. Mirault, I. Netuka, CL. Guerin, DM. Smadja

520    9_

$a The Aeson® total artificial heart (A-TAH) has been developed as a total heart replacement for patients at risk of death from biventricular failure. We previously described endothelialization of the hybrid membrane inside A-TAH probably at the origin of acquired hemocompatibility. We aimed to quantify vasculogenic stem cells in peripheral blood of patients with long-term A-TAH implantation. Four male adult patients were included in this study. Peripheral blood mononuclear cells were collected before A-TAH implantation (T0) and after implantation at one month (T1), between two and five months (T2), and then between six and twelve months (T3). Supervised analysis of flow cytometry data confirmed the presence of the previously identified Lin-CD133+CD45- and Lin-CD34+ with different CD45 level intensities. Lin-CD133+CD45-, Lin-CD34+CD45- and Lin-CD34+CD45+ were not modulated after A-TAH implantation. However, we demonstrated a significant mobilization of Lin-CD34+CD45dim (p = 0.01) one month after A-TAH implantation regardless of the expression of CD133 or c-Kit. We then visualized data for the resulting clusters on a uniform manifold approximation and projection (UMAP) plot showing all single cells of the live Lin- and CD34+ events selected from down sampled files concatenated at T0 and T1. The three clusters upregulated at T1 are CD45dim clusters, confirming our results. In conclusion, using a flow cytometry approach, we demonstrated in A-TAH-transplanted patients a significant mobilization of Lin-CD34+CD45dim in peripheral blood one month after A-TAH implantation. Using a flow cytometry approach, we demonstrated in A-TAH transplanted patients a significant mobilization of Lin-CD34+CD45dim in peripheral blood one month after A-TAH implantation. This cell population could be at the origin of newly formed endothelial cells on top of hybrid membrane in Carmat bioprosthetic total artificial heart.

650    _2

$a dospělí $7 D000328

650    _2

$a antigeny CD34 $7 D018952

650    12

$a endoteliální buňky $7 D042783

650    12

$a umělé srdce $7 D006354

650    _2

$a lidé $7 D006801

650    _2

$a leukocyty mononukleární $7 D007963

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a kmenové buňky $7 D013234

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Detriché, Grégoire $u Innovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France $u Vascular Medicine Department and Georges Pompidou European Hospital, AP-HP, 75015, Paris, France

700    1_

$a Gendron, Nicolas $u Innovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France $u Hematology and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, 75015, Paris, France

700    1_

$a Philippe, Aurélien $u Innovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France $u Hematology and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, 75015, Paris, France

700    1_

$a Latremouille, Christian $u Carmat SA, Vélizy-Villacoublay, France

700    1_

$a Soret, Lou $u Innovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France $u Hematology and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, 75015, Paris, France

700    1_

$a Capel, Antoine $u Carmat SA, Vélizy-Villacoublay, France

700    1_

$a Peronino, Christophe $u Innovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France $u Hematology and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, 75015, Paris, France $u Carmat SA, Vélizy-Villacoublay, France

700    1_

$a Jansen, Piet $u Carmat SA, Vélizy-Villacoublay, France

700    1_

$a Ivak, Peter $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Carpentier, Alain $u Cardiac Surgery Department and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, Université de Paris, 75015, Paris, France

700    1_

$a Mirault, Tristan $u Vascular Medicine Department and Georges Pompidou European Hospital, AP-HP, 75015, Paris, France $u PARCC, INSERM, Université de Paris, 75015, Paris, France

700    1_

$a Netuka, Ivan $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Guerin, Coralie L $u Institut Curie, Cytometry Platform, 75006, Paris, France $u Innovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France

700    1_

$a Smadja, David M $u Innovative Therapies in Haemostasis, INSERM, Université de Paris, 75006, Paris, France. david.smadja@aphp.fr $u Hematology and Biosurgical Research Lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, 75015, Paris, France. david.smadja@aphp.fr

773    0_

$w MED00205753 $t Stem cell reviews and reports $x 2629-3277 $g Roč. 17, č. 6 (2021), s. 2332-2337

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34622384 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220720 $b ABA008

991    __

$a 20220804135828 $b ABA008

999    __

$a ok $b bmc $g 1823008 $s 1170870

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 17 $c 6 $d 2332-2337 $e 20211007 $i 2629-3277 $m Stem cell reviews and reports $n Stem Cell Rev Rep $x MED00205753

LZP    __

$a Pubmed-20220720